Sonoma Pharmaceuticals (SNOA) Return on Capital Employed (2011 - 2026)
Sonoma Pharmaceuticals (SNOA) posted quarterly Return on Capital Employed of 27.47% for Q1 2026, up 1124.0% year-over-year from 2.24% in Q1 2025, and up 5.44% quarter-over-quarter from 29.05% in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Return on Capital Employed (2011 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 27.47% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 1124.0% year-over-year to 27.47%; the TTM figure through Mar 2026 stood at 27.47% (up 1124.0% YoY), while the FY2026 annual figure was 27.36%, up 930.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 27.47%, up from 29.05% in the prior quarter.
- The five-year high for Return on Capital Employed was 27.47% in Q1 2026, with the low at 61.65% in Q4 2022.
- The 5-year median for Return on Capital Employed is 41.23% (2024), against an average of 41.34%.
- The sharpest annual moves came in 2022 and 2023: Return on Capital Employed slumped 2575 bps in 2022, then soared 2149 bps in 2023.
- Sonoma Pharmaceuticals' Return on Capital Employed stood at 61.65% in 2022, then jumped by 35 bps to 40.16% in 2023, then fell by 11 bps to 44.75% in 2024, then soared by 35 bps to 29.05% in 2025, then grew by 5 bps to 27.47% in 2026.
- Business Quant data shows SNOA's Return on Capital Employed at 27.47% in Q1 2026, 29.05% in Q4 2025, and 31.5% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Sonoma Pharmaceuticals | 5.17 Mn | -165,129.89 | 2.58 Mn | -13.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.28% |
| Mar 31, 2026 | -27.47% |
| Dec 31, 2025 | -29.05% |
| Sep 30, 2025 | -31.50% |
| Jun 30, 2025 | -39.07% |
| Mar 31, 2025 | -38.71% |
| Dec 31, 2024 | -44.75% |
| Sep 30, 2024 | -41.23% |
| Jun 30, 2024 | -44.32% |
| Mar 31, 2024 | -42.89% |
| Dec 31, 2023 | -40.16% |
| Sep 30, 2023 | -47.11% |
| Jun 30, 2023 | -41.19% |
| Mar 31, 2023 | -40.19% |
| Dec 31, 2022 | -61.65% |
| Sep 30, 2022 | -44.71% |
| Jun 30, 2022 | -44.40% |
| Mar 31, 2022 | -44.33% |
| Dec 31, 2021 | -35.89% |
| Sep 30, 2021 | -37.37% |